Lipocine (LPCN) Tax Provisions (2012 - 2025)
Lipocine's (LPCN) quarterly Tax Provisions came in at $200.0 in Q1 2025, little changed YoY from $200.0 in Q1 2024, and down 83.55% on a QoQ basis from $1216.0 in Q4 2024.
Lipocine (LPCN) Tax Provisions (2012 - 2025) Analysis & Trends
Lipocine (LPCN) has 14 years of Tax Provisions data on file, last reported at $200.0 in Q1 2025.
- Quarterly Tax Provisions changed 0.0% year-over-year to $200.0 in Q1 2025, while the trailing twelve-month figure through Sep 2025 was $1416.0 (up 100.04% YoY) and the FY2024 annual result came in at $1897.0, up 100.06% from the prior year.
- Tax Provisions slipped to $200.0 in Q1 2025, from $1216.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $1216.0 in Q4 2024 to a low of -$3.4 million in Q4 2023.
- A 5-year average of -$582425.0 and a median of $200.0 in 2021 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2022 — Tax Provisions tumbled 1593.99% — and 2024, when it surged 100.04%.
- Tracing LPCN's Tax Provisions over 5 years: stood at -$133382.0 in 2021, then plunged by 1593.99% to -$2.3 million in 2022, then tumbled by 51.99% to -$3.4 million in 2023, then surged by 100.04% to $1216.0 in 2024, then slumped by 83.55% to $200.0 in 2025.
- The last three Tax Provisions figures came in at $200.0 (Q1 2025), $1216.0 (Q4 2024), and $481.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 200.00 |
| Dec 31, 2024 | 1,216.00 |
| Jun 30, 2024 | 481.00 |
| Mar 31, 2024 | 200.00 |
| Dec 31, 2023 | -3.43 Mn |
| Mar 31, 2023 | 200.00 |
| Dec 31, 2022 | -2.26 Mn |
| Mar 31, 2022 | 200.00 |
| Dec 31, 2021 | -133,382.00 |
| Mar 31, 2021 | 200.00 |
| Dec 31, 2020 | -4.40 Mn |
| Mar 31, 2020 | 200.00 |
| Dec 31, 2019 | -2.73 Mn |
| Mar 31, 2019 | 200.00 |
| Dec 31, 2018 | -2.45 Mn |
| Mar 31, 2018 | 700.00 |
| Mar 31, 2017 | 700.00 |
| Dec 31, 2016 | 52.00 |
| Mar 31, 2016 | 700.00 |
| Mar 31, 2015 | 200.00 |